Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5965 in Primary IgA Nephropathy
NCT06137768Phase 2Completed
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Dec 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-5965 in IgA nephropathy (IgAN), sponsored by Chengdu Suncadia Pharmaceuticals. Started Dec 2023; status: completed.
02
Drugs
HRS-5965
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06137768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137768.